This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Approximately 9 studies were included in the review.
Methods of combining primary studies
The authors reported that they did not attempt meta-analyses of trials because of the need to summarise the surrogate end point (not consistently reported across trials) as well as relative reductions in cardiovascular end points.
Investigation of differences between primary studies
Results of the review
The nurse-led clinic reduced blood pressure by 1.2 mmHg, (p=0.21), and lipids by 0.28 mmol/L, (p=0.0004) in comparison with conventional care.
Drug treatment with statins reduced the mean total serum cholesterol by 1.7 mmol/L at one year. Statin treatment achieved a relative risk reduction of 27% (95% confidence interval, CI: 33 to 21) in MI and 25% (95% CI: 34 to 15) in stroke.
A significant reduction in mean arterial blood pressure of 5.7 mmHg was achieved by tight control after 1 year. Tight control achieved relative risk reductions in MI of 21% (95% CI: 41 to -7) and stroke 44% (95% CI: 65 to 11).
The quality-adjusted utility weight applied to each health state was 1 for healthy, 0.88 for post-MI and 0.5 for poststroke.
The cost per patient of the specialist clinic was $605 to achieve blood pressure control and $888 to achieve lipid control.
Blood pressure control treatment alone generated savings of $747 per patient, while lipid control treatment generated additional costs of $3,780.
Synthesis of costs and benefits
The costs and benefits were combined using an incremental cost-utility ratio (i.e. the additional cost per QALY gained). For blood pressure control treatment, the authors found savings of $1,400 per QALY gained. The incremental costutility ratio of lipid control treatment was $8,230 per QALY gained.
The authors calculated the cost-effectiveness of introducing specialist nurse-led clinics to improve the care of hospitalmanaged patients with diabetes. The change in surrogate outcome due to treatment was multiplied by the cost per patient of the specialist nurse clinic, then divided by the product of the QALYs gained through treatment and the change in surrogate outcome achieved by the specialist clinic. This ratio was then added to the treatment incremental cost-utility ratio (reported above). Hence, for example, the cost-effectiveness of a specialist clinic for blood pressure control would be calculated as follows: (5.7 x 605)/(0.53 x 1.2) -1,400.
Therefore, the incremental cost-utility ratio for specialist clinics was $4,020 per QALY gained for blood control pressure and $19,950 per QALY gained for lipid control.
The results of the sensitivity analysis showed that, at a cost-effectiveness threshold of $50,000 per QALY gained, the probability that the blood pressure clinic was cost-effective was 77%, the probability that the lipid control clinic was cost-effective was 99%, and the probability of a combined clinic being cost-effective was 83%.
